Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Biological Safety Testing Products and Services Market

ID: MRFR/LS/5336-HCR
100 Pages
Rahul Gotadki
Last Updated: April 15, 2026

Biologics Safety Testing Market Research Report By Testing Type (Sterility Testing, Endotoxin Testing, Bioburden Testing, Validation Testing), By Product Type (Reagents, Kits, Services), By Application (Vaccine Development, Therapeutics, Blood and Blood Products, Cellular and Gene Therapy), By End Use (Pharmaceutical Companies, Biotechnology Companies, Research Institutions) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Biologics Safety Testing Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Application (USD Million) | |
      1. 4.1.1 Cell Line Development | |
      2. 4.1.2 Bioburden Testing | |
      3. 4.1.3 Sterility Testing | |
      4. 4.1.4 Endotoxin Testing | |
      5. 4.1.5 Virus Safety Testing |
    2. 4.2 Healthcare, BY Test Type (USD Million) | |
      1. 4.2.1 Biological Assays | |
      2. 4.2.2 Molecular Assays | |
      3. 4.2.3 Microbial Assays | |
      4. 4.2.4 Cell-Based Assays | |
      5. 4.2.5 Immunological Assays |
    3. 4.3 Healthcare, BY End User (USD Million) | |
      1. 4.3.1 Pharmaceutical Companies | |
      2. 4.3.2 Biotechnology Companies | |
      3. 4.3.3 Contract Research Organizations | |
      4. 4.3.4 Academic Research Institutes | |
      5. 4.3.5 Government Agencies |
    4. 4.4 Healthcare, BY Region (USD Million) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Charles River Laboratories (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Eurofins Scientific (FR) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Sartorius AG (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Merck KGaA (DE) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Thermo Fisher Scientific (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Lonza Group (CH) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 WuXi AppTec (CN) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Boehringer Ingelheim (DE) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 SGS SA (CH) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY APPLICATION |
    7. 6.4 US MARKET ANALYSIS BY TEST TYPE |
    8. 6.5 US MARKET ANALYSIS BY END USER |
    9. 6.6 CANADA MARKET ANALYSIS BY APPLICATION |
    10. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY END USER |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY APPLICATION |
    14. 6.11 GERMANY MARKET ANALYSIS BY TEST TYPE |
    15. 6.12 GERMANY MARKET ANALYSIS BY END USER |
    16. 6.13 UK MARKET ANALYSIS BY APPLICATION |
    17. 6.14 UK MARKET ANALYSIS BY TEST TYPE |
    18. 6.15 UK MARKET ANALYSIS BY END USER |
    19. 6.16 FRANCE MARKET ANALYSIS BY APPLICATION |
    20. 6.17 FRANCE MARKET ANALYSIS BY TEST TYPE |
    21. 6.18 FRANCE MARKET ANALYSIS BY END USER |
    22. 6.19 RUSSIA MARKET ANALYSIS BY APPLICATION |
    23. 6.20 RUSSIA MARKET ANALYSIS BY TEST TYPE |
    24. 6.21 RUSSIA MARKET ANALYSIS BY END USER |
    25. 6.22 ITALY MARKET ANALYSIS BY APPLICATION |
    26. 6.23 ITALY MARKET ANALYSIS BY TEST TYPE |
    27. 6.24 ITALY MARKET ANALYSIS BY END USER |
    28. 6.25 SPAIN MARKET ANALYSIS BY APPLICATION |
    29. 6.26 SPAIN MARKET ANALYSIS BY TEST TYPE |
    30. 6.27 SPAIN MARKET ANALYSIS BY END USER |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY APPLICATION |
    36. 6.33 CHINA MARKET ANALYSIS BY TEST TYPE |
    37. 6.34 CHINA MARKET ANALYSIS BY END USER |
    38. 6.35 INDIA MARKET ANALYSIS BY APPLICATION |
    39. 6.36 INDIA MARKET ANALYSIS BY TEST TYPE |
    40. 6.37 INDIA MARKET ANALYSIS BY END USER |
    41. 6.38 JAPAN MARKET ANALYSIS BY APPLICATION |
    42. 6.39 JAPAN MARKET ANALYSIS BY TEST TYPE |
    43. 6.40 JAPAN MARKET ANALYSIS BY END USER |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY END USER |
    50. 6.47 THAILAND MARKET ANALYSIS BY APPLICATION |
    51. 6.48 THAILAND MARKET ANALYSIS BY TEST TYPE |
    52. 6.49 THAILAND MARKET ANALYSIS BY END USER |
    53. 6.50 INDONESIA MARKET ANALYSIS BY APPLICATION |
    54. 6.51 INDONESIA MARKET ANALYSIS BY TEST TYPE |
    55. 6.52 INDONESIA MARKET ANALYSIS BY END USER |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY END USER |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY APPLICATION |
    61. 6.58 BRAZIL MARKET ANALYSIS BY TEST TYPE |
    62. 6.59 BRAZIL MARKET ANALYSIS BY END USER |
    63. 6.60 MEXICO MARKET ANALYSIS BY APPLICATION |
    64. 6.61 MEXICO MARKET ANALYSIS BY TEST TYPE |
    65. 6.62 MEXICO MARKET ANALYSIS BY END USER |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY END USER |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY END USER |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million) |
    90. 6.87 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Million) |
    92. 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.2.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.2.3 BY END USER, 2025-2035 (USD Million) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.3.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.3.3 BY END USER, 2025-2035 (USD Million) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.4.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.4.3 BY END USER, 2025-2035 (USD Million) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.5.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.5.3 BY END USER, 2025-2035 (USD Million) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.6.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.6.3 BY END USER, 2025-2035 (USD Million) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.7.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.7.3 BY END USER, 2025-2035 (USD Million) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.8.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.8.3 BY END USER, 2025-2035 (USD Million) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.9.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.9.3 BY END USER, 2025-2035 (USD Million) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.10.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.10.3 BY END USER, 2025-2035 (USD Million) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.11.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.11.3 BY END USER, 2025-2035 (USD Million) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.12.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.12.3 BY END USER, 2025-2035 (USD Million) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.13.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.13.3 BY END USER, 2025-2035 (USD Million) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.14.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.14.3 BY END USER, 2025-2035 (USD Million) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.15.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.15.3 BY END USER, 2025-2035 (USD Million) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.16.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.16.3 BY END USER, 2025-2035 (USD Million) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.17.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.17.3 BY END USER, 2025-2035 (USD Million) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.18.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.18.3 BY END USER, 2025-2035 (USD Million) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.19.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.19.3 BY END USER, 2025-2035 (USD Million) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.20.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.20.3 BY END USER, 2025-2035 (USD Million) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.21.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.21.3 BY END USER, 2025-2035 (USD Million) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.22.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.22.3 BY END USER, 2025-2035 (USD Million) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.23.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.23.3 BY END USER, 2025-2035 (USD Million) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.24.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.24.3 BY END USER, 2025-2035 (USD Million) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.25.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.25.3 BY END USER, 2025-2035 (USD Million) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.26.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.26.3 BY END USER, 2025-2035 (USD Million) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.27.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.27.3 BY END USER, 2025-2035 (USD Million) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.28.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.28.3 BY END USER, 2025-2035 (USD Million) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.29.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.29.3 BY END USER, 2025-2035 (USD Million) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million) | |
      2. 7.30.2 BY TEST TYPE, 2025-2035 (USD Million) | |
      3. 7.30.3 BY END USER, 2025-2035 (USD Million) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Cell Line Development
  • Bioburden Testing
  • Sterility Testing
  • Endotoxin Testing
  • Virus Safety Testing

Healthcare By Test Type (USD Million, 2025-2035)

  • Biological Assays
  • Molecular Assays
  • Microbial Assays
  • Cell-Based Assays
  • Immunological Assays

Healthcare By End User (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
  • Government Agencies

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions